One shot for two threats: new mRNA combo vaccine enters human testing

NCT ID NCT07464314

First seen Mar 25, 2026 · Last updated May 10, 2026 · Updated 7 times

Summary

This early-stage study tests a new mRNA vaccine that aims to protect against both seasonal flu and COVID-19 with a single shot. About 225 healthy adults aged 65 to 85 will receive either the combo vaccine, a standard flu vaccine, or a COVID-19 vaccine. Researchers will monitor side effects and measure how well the body builds defenses against both viruses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN+COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GSK Investigational Site

    RECRUITING

    San Diego, California, 92123, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • GSK Investigational Site

    RECRUITING

    Miami, Florida, 33186, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.